New Era of Preventing End-Stage Kidney Disease Act
- Last Action
- 2/24/2025
Actions
- 2025-02-24Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2025-02-24Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2025-02-24Introduced in House
- 2025-02-24Introduced in House
CRS Summary
As of 2025-02-24 (00)
New Era of Preventing End-Stage Kidney Disease Act
This bill establishes regional centers of excellence, postgraduate fellowships, and training for health professionals relating to the diagnosis and treatment of rare kidney disease. It also requires the Department of Health and Human Services (HHS) to conduct various studies on rare kidney disease.
Specifically, it authorizes the National Institute of Diabetes and Digestive and Kidney Diseases to award funding to public and private nonprofit entities for establishing regional centers of excellence that will increase public awareness, conduct research, and develop resources for diagnosing and treating rare kidney diseases. A center may receive such funding for up to five years, unless extended by the institute.
The bill also requires health professions schools receiving a grant from the Health Resources and Services Administration (HRSA) Centers of Excellence program to award fellowships for training on preventing, diagnosing, and treating rare kidney disease in disproportionately impacted populations.
Also, the bill expands the priorities of HRSA’s Primary Care Training and Enhancement program to include training for health care workers to care for individuals with kidney disease.
Additionally, HHS must conduct several studies and report to Congress on topics such as treating rare kidney disease in disproportionately affected populations, eliminating the need for dialysis or kidney transplants, and increasing public awareness of rare kidney disease.
Cosponsors (20)
- Terri Sewell (D-AL)
- Carol Miller (R-WV)
- Scott Peters (D-CA)
- Troy Balderson (R-OH)
- Paul Tonko (D-NY)
- Bradley Schneider (D-IL)
- Danny Davis (D-IL)
- Ted Lieu (D-CA)
- Neal Dunn (R-FL)
- Brian Fitzpatrick (R-PA)
- Dan Crenshaw (R-TX)
- Eleanor Norton (D-DC)
- Thomas Suozzi (D-NY)
- Julia Brownley (D-CA)
- Jay Obernolte (R-CA)
- Michael Lawler (R-NY)
- Kathy Castor (D-FL)
- Donald Davis (D-NC)
- Joe Wilson (R-SC)
- Rashida Tlaib (D-MI)
Subjects
- Congressional oversight
- Digestive and metabolic diseases
- Genetics
- Government studies and investigations
- Health care coverage and access
- Health programs administration and funding
- Health promotion and preventive care
- Medical education
- Medical research
- Medical tests and diagnostic methods
- Research administration and funding
Sourced from Congress.gov (public domain).
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.